Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Aquestive Therapeutics, Inc. develops and manufactures specialty pharmaceutical products using proprietary oral-film and drug-delivery technologies. News about AQST centers on the company’s proprietary pipeline, including Anaphylm™ (dibutepinephrine) sublingual film for Type I allergic reactions, including anaphylaxis, and AQST-108, an epinephrine prodrug topical gel being explored for dermatological conditions such as alopecia areata.
Recurring updates also cover FDA interactions and NDA communications for Anaphylm, pharmacokinetic and human-factor study topics, quarterly financial results, licensee and CDMO manufacturing activity, investor presentations, equity inducement grants, and legal, compliance, and board-governance changes.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced it will report its second-quarter results for the period ended June 30, 2022, on August 2, 2022, after market close. Investors can join a conference call on August 3, 2022, at 8:00 a.m. ET, after prior registration. The company focuses on innovative delivery methods for complex molecules and has five commercialized products and a late-stage pipeline targeting central nervous system diseases and severe allergic reactions. For more information, visit Aquestive's website.
Aquestive Therapeutics (AQST) announced positive topline results from Part 3 of the EPIPHAST study for AQST-109, an epinephrine oral film. Key findings showed a consistent Tmax of 12 minutes for sublingual administration after consuming a peanut butter sandwich, with comparable pharmacokinetics to previous datasets. In addition, swallowing the film whole with water resulted in unexpectedly high gastrointestinal absorption, indicating improved compliance potential. The ongoing EPIPHAST II study will compare AQST-109 to standard epinephrine injection methods.
Aquestive Therapeutics (AQST) announced promising results from the EPIPHAST study for AQST-109, an oral film for anaphylaxis treatment. The study demonstrated a median time to maximum concentration (Tmax) of 12 minutes, significantly faster than traditional EpiPen's 50 minutes. AQST-109 shows favorable pharmacokinetics and safety profiles. An upcoming head-to-head study with EpiPen is set for Q3 2022, with plans to seek an End-of-Phase 2 meeting with the FDA shortly thereafter.
Aquestive Therapeutics (NASDAQ: AQST) has completed a registered direct offering, raising approximately $8.5 million by selling 8,850,000 shares at $0.96 each to an institutional investor and $1.09 for its executives. The warrants issued are exercisable after six months at a price of $0.96. CEO Daniel Barber emphasized the focus on profitability and cash generation amidst market challenges, particularly regarding the FDA review of Libervant and the development of AQST-109. The offering is executed under Form S-3 registration with the SEC.
Aquestive Therapeutics (NASDAQ: AQST) announced participation in the JMP Securities Life Sciences Conference on June 15-16, 2022. The management team will conduct a fireside chat on June 16 at 9:00 am ET and hold investor meetings throughout the conference. A webcast of the presentation will be available on the company's Investor Relations website for 30 days post-event. Aquestive focuses on developing innovative oral medications to enhance patient care, with five products currently on the market, including Sympazan® for seizure treatment.
Aquestive Therapeutics (NASDAQ: AQST) announced a definitive agreement for a registered direct offering of 8,850,000 shares of common stock and warrants, generating approximately $8.5 million in gross proceeds. Shares will be sold at $0.96 each to a healthcare-focused institutional investor and at $1.09 to certain executives. The offering is expected to close around June 8, 2022, pending customary conditions. The funds will be allocated for general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent for this offering.
Aquestive Therapeutics (NASDAQ: AQST) announces a leadership change with Daniel Barber appointed as the new President and CEO, succeeding Keith Kendall, who is leaving the company. Barber, previously the COO, will also join the Board of Directors. Kendall, who has been with the company since its inception, will serve as a consultant until the year's end to ensure a smooth transition. The company emphasized that Kendall's departure is unrelated to its financial performance or strategy. Barber aims to focus on key product candidates like Libervant and AQST-109 while managing costs.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The management team will present on May 25 at 2:30 PM ET and will host investor meetings throughout the event. A webcast of the presentation will be accessible on the company's Investors webpage, with a replay available for 30 days post-event. The company focuses on innovative therapies, including five commercialized products and ongoing development of its proprietary pipeline aimed at CNS diseases and severe allergic reactions.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) reported financial results for Q1 2022 with total revenues of $12.3 million, up from $11.1 million in Q1 2021. However, the company posted a net loss of $13.2 million, improved from $14.7 million in the prior year. Key developments include the commencement of Part 3 of the EPIPHAST trial for AQST-109 and the ongoing orphan drug exclusivity review for Libervant by the FDA. The company anticipates full-year revenues between $42 million and $47 million.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced it will report its Q1 results for the period ending March 31, 2022, on May 3, 2022, after market close. A conference call for investors is scheduled for May 4, 2022, at 8:00 a.m. ET, accessible via phone or a live webcast on their website. The company specializes in developing innovative orally administered products targeting CNS diseases and severe allergic reactions. Notably, it has five commercialized products and a pipeline that includes proprietary and licensed drug candidates.